Results 11 to 20 of about 14,919 (139)

Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. [PDF]

Cancer Sci
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Ikeda S, Hasegawa K, Takahama T, Kachi K, Yanagisawa A, Kawakami S, Yoshida M, Sakai M, Watanabe S, Nakagawa K.   +9 more
europepmc   +2 more sources

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Child with RET proto-oncogene codon 634 mutation

The Turkish Journal of Pediatrics, 2017
Herein we reported a 7-year-old child with RET proto-oncogene c634 mutation. Her mother had been diagnosed with medullary thyroid carcinoma (MTC), and treated six years ago.
Dilek İnce, Kamer Mutafoglu, Erdener Özer, Ayhan Abacı, Filiz Hazan, Osman Zeki Karakuş, Hale Tuhan, Yeşim Oymak, Eda Ataseven, Bengü Demirağ, Nur Olgun   +10 more
doaj   +1 more source

Precision oncology for RET-related tumors

Frontiers in Oncology, 2022
Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) syndrome and in sporadic medullary thyroid cancer, while RET ...
Antonella Verrienti, Giorgio Grani, Marialuisa Sponziello, Valeria Pecce, Giuseppe Damante, Cosimo Durante, Diego Russo, Sebastiano Filetti   +7 more
doaj   +1 more source

Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2021
In the past 20 years, with the development of molecular biology, the treatment of non-small cell lung cancer (NSCLC) has been developing. Targeted therapy has improved the survival period of patients with positive mutation of tumor driver gene.
Yujun ZHENG, Wei JIANG, Dongyan CHEN, Yanjun LI, Lulu DAI, Lei HUANG, Mingji WANG   +6 more
doaj   +1 more source

Targeted therapy of RET fusion-positive non-small cell lung cancer

Frontiers in Oncology, 2022
Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with ...
Zixiong Shen, Binxu Qiu, Lin Li, Bo Yang, Guanghu Li   +4 more
doaj   +1 more source

Multiple endocrine neoplasias type 2B and RET proto-oncogene

Italian Journal of Pediatrics, 2012
Multiple Endocrine Neoplasia type 2B (MEN 2B) is an autosomal dominant complex oncologic neurocristopathy including medullary thyroid carcinoma, pheochromocytoma, gastrointestinal disorders, marphanoid face, and mucosal multiple ganglioneuromas ...
Martucciello Giuseppe, Lerone Margherita, Bricco Lara, Tonini Gian, Lombardi Laura, Del Rossi Carmine G, Bernasconi Sergio   +6 more
doaj   +1 more source

Sonographic Findings of Medullary Thyroid Carcinoma Leading to Diagnosis of Multiple Endocrine Neoplasia Type 2a during Pregnancy

American Journal of Perinatology Reports, 2011
Multiple endocrine neoplasia (MEN) type 2a (Sipple's syndrome) is characterized by medullary thyroid carcinoma and pheochromocytoma, and in a smaller percentage of cases, multiglandular parathyroid hyperplasia.
David M. Sherer, Mudar Dalloul, Ghadir Salame, Tana Shah, Eli Serur, Harry L. Zinn, Ovadia Abulafia   +6 more
doaj   +1 more source

A germline RET proto-oncogene mutation in multiple members of an Arab family with variable onset of MEN type 2A-associated clinical manifestations

Egyptian Journal of Medical Human Genetics, 2017
Background: Multiple endocrine neoplasia type 2A (MEN2A) is a rare cancer associated-syndrome, inherited in an autosomal dominant fashion and caused by germline mutation in RET proto-oncogene.
Makia Marafie, Ibrahim Suliman, Mohammed Dashti, Abdulla Redha, Abdulrahman Alshati   +4 more
doaj   +1 more source

RET proto-oncogene mutations in the Slovenian population of patients with medullary thyroid cancer

Onkologija, 2020
Background. Medullary thyroid cancer (MTC) is a rare, endocrine tumour that occurs as part of hereditary cancer syndrome in approximately 25% of cases and develops as a sporadic form in 75%.
Sara Milićević, Damijan Bergant, Tina Žagar, Barbara Perić   +3 more
doaj   +1 more source